Snwv   corporate investor presentation - june 2014 - final
Upcoming SlideShare
Loading in...5
×

Like this? Share it with your network

Share
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
441
On Slideshare
224
From Embeds
217
Number of Embeds
2

Actions

Shares
Downloads
2
Comments
0
Likes
0

Embeds 217

http://www.redchip.com 216
http://www.slideee.com 1

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Healing today. Curing tomorrow. OTCQB: SNWV June 2014 Applying shockwave technology to repair and regenerate skin, musculoskeletal tissue, and vascular structures
  • 2. 2 This presentation may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval process and subsequent marketing of the Company's product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, fluctuations in the Company's quarterly results, the Company's ability to continue and manage its growth, liquidity and other capital resources issues, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward- looking statement.
  • 3. 3 SANUWAVE Health (SNWV), Inc. is an emerging regenerative medicine company focused on the development and commercialization of patented non- invasive, biological response activation devices for the repair and regeneration of tissue, musculoskeletal and vascular structures. The Diabetic Foot Ulcer Wound Market Is Our First Focus
  • 4. 4  Proprietary technology uses focused shock waves – PACE® (Pulsed Acoustic Cellular Expression)  Lead product, dermaPACE® in U.S. PMA clinical trial supplement for diabetic foot ulcers  Completed minimum enrollment in Q2-2014 – independent data monitoring committee review of the 90 patients after completion of the 12 week efficacy phase in Q3-2014  PMA submission in Q4-14/Q1-15 with approval in 2015; pending positive trial results  Lower cost treatment and non-invasive • Large and growing wound care market - $3B U.S. for DFU’s, $22B Worldwide  Completed a $9.3M private placement in March 2014 led by RA Capital, a leading life sciences investment fund providing capital to FDA approval, pending positive trial results  Proven technology – OssaTron® has 21 years market experience  Approved devices in Europe, Australia, S. Korea and GCC – expanding distribution  Significant future applications – medical and non-medical  Extensive patent portfolio – 38 patents (issued or pending)
  • 5. 5  Patented, non-invasive devices for the repair and regeneration of:  Skin  Musculoskeletal tissue  Vascular structures  Devices activate biologic signaling and angiogenic responses, producing:  New vascularization  Microcirculatory improvement Immediate microcirculatory improvement Growth factor up- regulation
  • 6. $5B $4B $1B $1B $1B 6 • Diabetic Foot Ulcer • Chronic Mixed Wounds • Pressure Sores • Infections and biofilms • Burns Advanced Wound Care • Sports Medicine • Tendon / Pain • Trauma / Fracture • Osteoarthritis • Spine Orthopedics • Scar Modulation • Reconstructive and Grafting • Body Contouring • Peripheral Artery Disease • Atherosclerosis • Myocardial Ischemia Plastic/Cosmetic Vascular/CardiacStem Cells • Stem Cell Proliferation • Soft Tissue Regeneration
  • 7. 7 U.S. Market  Diabetic Foot Ulcers - $3B+  27 million people living with diabetes and 79 million pre-diabetics.  25% of diabetics will acquire a non- healing ulcer in their lifetime; ~1.5+ million diabetic ulcers annually.  Diabetic foot ulcers lead to over 82,000 amputations annually at a cost that are estimated to exceed $3.6 billion annually.  Hospitalization costs of ~$20,000 for a patient with a DFU; ~$60,000 for an amputation. International Market  Globally there are 366 million people living with diabetes and it is expected to reach 552 million by 2030, an increase of 50.7%.  dermaPACE is CE Marked and currently marketed by independent distributors in Spain, Australia, Canada, and the Middle East.  dermaPACE can be licensed or joint ventured in these markets to speed market penetration while minimizing operating costs. The international global wound care market of $22 billion offers significant expansion opportunity for CE marked dermaPACE
  • 8. Treatment Advantages  Robust closure with extremely low recurrence rates  Non-invasive, convenient and safe  Mechanism of action (MOA) allows  Accelerated tissue repair—may decrease long-term DFU complications  Increased blood flow (perfusion) and increased vascularization (angiogenesis)  Restores oxygenation to ischemic area  Cost-effective  May be used as an adjunct therapy 8
  • 9. 9 Design  Double-blinded, randomized, sham-controlled  90 patient minimum at 20 U.S and Canadian sites  Doubled the number of treatments - Up to 8 total treatments - 4 dermaPACE treatments administered bi-weekly in first 2 weeks, then 4 additional treatments between weeks 4 and 10 following enrollment  Standardized debridement procedures, central independent review by Core Lab of wound images for closure determinations, and concise training materials  Primary endpoint: complete wound closure at 12 weeks Rationale  FDA approval of Bayesian Statistics - layering original plus supplemental results - requires smaller patient population to achieve FDA approval  Scientific research (published after original trial initiated in 2007) supports additional treatments during trial
  • 10. 10 100% of minimum number of patients enrolled  Completed minimum 90 patient enrollment in Q2-2014  Independent data monitoring committee review of the 90 patients after completion of the 12 week efficacy phase in Q3-2014  PMA submission in Q4-2014/Q1-2015  Potential U.S. approval in 2015, pending positive trial results IDE Supplement Approval CRO Database Development First Enrollment Minimum Enrollment 90th Patient Follow Up for Closure Submit PMA 4Q 2012 1Q / 2Q 2013 2Q 2013 2Q 2014 3Q 2014 4Q-2014/ 1Q-2015
  • 11. 11  SANUWAVE’s business model is a per procedure pricing model  RFID card readers are built into each generator box. Sell procedure kit with procedure specific protocol cards that activate the device  Patients receive four, 20-minute, noninvasive procedures of 500 impulses over a two-week period and then additional maintenance treatments at weeks 4, 6, 8, and 10 to maintain optimum healing environment if necessary dermaPACE being used to treat a diabetic foot ulcer. RFID Protocol Card
  • 12. 12 Potentially less than half the cost of existing therapies $0 $2,000 $4,000 $6,000 $8,000 $10,000 $12,000 $14,000 $16,000 PACE NPWT Apigraf Dermagraft $3,700 $13,900 $8,100 $11,600 Advanced Modality Cost Comparison for DFU Treatment dermaPACE offers: Non-invasive treatment Lowest total treatment cost Convenient, efficient treatments for clinicians and patients Significantly lower recurrence rates Estimated costs associated with full 12 weeks of DFU treatment including physician and nursing time, facility charges, treatment costs and associated standard of care. NPWT - Based on 16 weeks of DFU treatment of NPWT in accordance with RCT. Apigraf - Based on an average of 4 surgical applications (per Policy up to 5 surgical applications are allowed) Dermagraft - Based on an average of 6 surgical applications (per Policy up to 8 applications are allowed) *Data on File – Based on published reports/literature *The dermaPACE device is currently the subject of an Investigational Device Exemption (IDE) study and is not available or for sale in the United States.
  • 13. 13 Seek relationships with qualified partners and JV/licensing agreements  Address advanced wound care market - large and growing  Serve other medical markets – stem cells, orthopedics, plastic/cosmetic, vascular/cardiac  Expand to non-medical industrial applications (energy production, water cleaning, biofilm destruction) Advanced Wound Care Other Medical Markets Industrial Applications
  • 14. 14 Addressable Opportunities Covered by Patents Energy Production  Advanced Fracking  Improved / Enhanced Oil Extraction Recovery Food Industry  Preservation  Milk  Fruit Juices  Meat Tenderizing Water  Fracking Water Cleaning  Industrial Water Cleaning  Drinking Water Cleaning Industrial Biofilms  Biofilm Destruction  Industrial Equipment  Cosmetic/Food Industry Equipment
  • 15. 15 Cash and Cash Equivalents - March 31, 2014 $7.2M (1) Shares Outstanding 47.0M Warrants and Options 61.1M Long-term Notes Payable – March 31, 2014 $5.4M (1) In March 2014, the Company completed a financing led by Boston-based healthcare crossover fund RA Capital Management, LLC
  • 16. 16 Kevin Richardson II, Chairman of the Board – Joined August 2005  Joined the Company as chairman of the board of directors in August of 2005. Brings a broad array of financial knowledge for healthcare information technology, financial services, business services and other industries. Since 2004, Mr. Richardson founded and has served as managing partner of Prides Capital LLC, an investment management firm. Daniel Jorgensen, M.D., M.P.H, CMO – Joined May 2013  15+ years experience in research, development, clinical, regulatory and commercialization activities at biotech and large pharmaceutical companies. Previously with PolyMedix and Pfizer. Iulian Cioanta, Ph.D., VP R&D – Joined in 2007  18+ years experience in medical device industry. Previously with Cordis Endovascular, a Johnson & Johnson company, Kensey Nash Corporation, ArgoMed Inc. and the Institute for the Design of Research Apparatuses. Barry Jenkins, CFO & COO – Joined in 2006  CPA with 30 years financial management experience. Previously with Snowden-Pencer, Inc., (sold to Cardinal Health), Automatic Data Processing (ADP), and Price Waterhouse. Peter Stegagno, VP Regulatory Affairs, Quality, and Operations – Joined 2006  20+ years experience in medical device market encompassing manufacturing, design and development, quality assurance and international and domestic regulatory affairs.
  • 17. 17  Lead product, dermaPACE® advancing in U.S. Phase III PMA supplemental DFU trial  Minimum enrollment (90th patient) completed in Q2-2014  PMA submission in Q4-14/Q1-15  FDA approval in 2015; pending positive trial results  Lower cost treatment and non-invasive  Significant future applications – medical and non-medical  Extensive patent portfolio- 38 issued or pending patents *Company valuations based on closing stock prices on May 23, 2014  $9.3M capital raise in March 2014 provides necessary capital to FDA approval  Valuation of SNWV ($22M); DSCI ($237M); MDWD ($265M); OSIR ($556M)*  Make application to a National Exchange in Q4 2014 or Q1 2015
  • 18. Healing today. Curing tomorrow. OTCQB: SNWV SANUWAVE Health, Inc. 11475 Great Oaks Way, Suite 150 Alpharetta, GA 30022 info@sanuwave.com +1(770) 419-7525